Immune checkpoint inhibitors (ICIs), particularly antibodies targeting programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1), have exhibited promising potential at improving tumor response and survival of HCC patients. The gene discussed is CD274; the disease is hepatocellular carcinoma.